

MDMA (Molly, Ecstasy)

Selected References:

- Barenys M. 2009. Chronic exposure to MDMA (ecstasy) increases DNA damage in sperm and alters testes histopathology in male rats. *Toxicol Lett* 191:40-46
- Barneys M, et al. 2020. Developmental neurotoxicity of MDMA. A systematic literature review summarized in a putative adverse outcome pathway. *Neurotoxicology* 78:209-241.
- Committee on Drugs, American Academy of Pediatrics. 2001. The transfer of drugs and other chemicals into human milk. *Pediatrics* 108:776-89.
- Cooper AJ & Egleston CV. 1997. Accidental ingestion of Ecstasy by a toddler: Unusual cause for convulsion in a febrile child. *J Accid Emerg Med* 14(3):183-184.
- Draper ES, et al. 2008. Recreational drug use. A major risk factor for gastroschisis? *Am J Epidemiol* 167(4):485-491.
- Fríguls B, et al. A comprehensive review of assay methods to determine drugs in breast milk and the safety of breastfeeding when taking drugs. *Anal Bioanal Chem* 397:1157-1179.
- Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA. 2008. Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. *Ther Drug Monit.* Jun;30(3):320-32.
- Marcela C, et al. 2019. Stimulant use in pregnancy – An under-recognized epidemic among pregnant women. *Clin Obstet* 62(1):168-184.
- McElhatton P, et al. 1999. Congenital anomalies after prenatal ecstasy exposure. *Lancet* 354:1441-2.
- Parrott A, et al. 2014. MDMA and heightened cortisol: a neurohormonal perspective on the pregnancy outcomes of mothers used 'Ecstasy' during pregnancy. *Hum Psychopharmacol* 29(1):1-7.
- Plessinger M, 1998. Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy. *Obstet Gynecol Clin North Am* 25:119-38.
- Singer LT, et al. 2012. Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy. *Neurotoxicol Teratol* 34(3):303-10.
- Singer L. et al 2012. One-year outcomes of prenatal exposure to MDMA and other recreational drugs. *Pediatrics* 130(3): 407-413.
- Singer LT, et al. 2015. Developmental outcomes of 3,4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK *Hum Psychopharmacol* 30(4): 290-294.
- Singer LT, et al. 2016. Motor delays in MDMA (ecstasy) exposed infants persist to 2 years. *Neurotoxicol Teratol* 54: 22-28.
- Smid MC, et al. 2019. Stimulant use in pregnancy: An under-recognized epidemic among pregnant women. *Clin Obstet Gynecol* 62(1):168-184.
- van Tonningen-van Driel MM, et al. 1999. [Pregnancy outcome after ecstasy use; 43 cases followed by the Teratology Information Service of the National Institute for Public Health and Environment (RIVM)]. *Ned Tijdschr Geneeskd* 143(1):27-31.
- Wouldes TA, Lester BM. 2019. Stimulants: How big is the problem and what are the effects of prenatal exposure? *Semin Fetal Neonatal Med* 24(2):155-160.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, July 1, 2022.

MDMA (Molly, Ecstasy)

Selected References:

- Banihani SA, Khasawneh FH. 2018. Effect of lansoprazole on human sperm motility, sperm viability, seminal nitric oxide production, and seminal calcium chelation. *Res Pharm Sci.*13:460-468.
- Dağlı U, Kalkan IH. 2017. Treatment of reflux disease during pregnancy and lactation. *Turk J Gastroenterol.* 2017 Dec;28(Suppl 1):S53-S56.
- Diav-Citrin O, et al. 2005. The safety of proton pump inhibitors in pregnancy: A multicenter prospective controlled trial. *Aliment Pharmacol Ther.* 21:269-75.
- Escoffier, J, Arnaud, B, Kaba, M, et al. 2020. Pantoprazole, a proton-pump inhibitor, impairs human sperm motility and capacitation in vitro. *Andrology.* 8: 1795- 1804.
- Hastie R et al. 2019. Proton Pump Inhibitors and Preeclampsia Risk Among 157 720 Women. *Hypertension.* 73(5):1097-1103. doi: 10.1161/HYPERTENSIONAHA.118.12547.
- Kallen BA. 2001. Use of omeprazole during pregnancy-no hazard demonstrated in 955 infants exposed during pregnancy. *Eur J Obstet Gynecol Reprod Biol.* 96(1):63-68.
- Mahadevan U, Kane S. 2006. American Gastroenterological Association Institute technical review on the use of gastrointestinal medications in pregnancy. *Gastroenterology.*131(1):283-331
- Majithia R, Johnson DA. 2012. Are proton pump inhibitors safe during pregnancy and lactation? Evidence to date. *Drugs.* 72(2):171-179.
- Marshall JK, et al. 1998. Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation. *Can J Gastroenterol.* 12(3):225-7.
- Matok I, et al. 2012. The safety of fetal exposure to proton-pump inhibitors during pregnancy. *Dig Dis Sci.* 57(3):699-705.
- Pasternak B, Hviid A. 2010. Use of proton pump inhibitors in early pregnancy and the risk of birth defects. *N Engl J Med.* 363(22): 2114-2123.
- Plante L, et al. 2004. Excretion of pantoprazole in human breast. *J Reprod Med.* 2004;49:825-7.
- Saito J, et al. 2020. Esomeprazole During Pregnancy and Lactation: Esomeprazole Levels in Maternal Serum, Cord Blood, Breast Milk, and the Infant's Serum. *Breastfeed Med.* 15(9):598-601. doi: 10.1089/bfm.2020.0175. Epub 2020 Jul 7.
- Ruigomez A, et al. 1999. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. *Am J Epidemiol.* 150(5):476-481.
- Thélin CS, Richter JE. 2020. Review article: the management of heartburn during pregnancy and lactation. *Aliment Pharmacol Ther.* 51(4):421-434. doi: 10.1111/apt.15611. Epub 2020 Jan 17. PMID: 31950535 Review.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.mothertobaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, July 1, 2022.

MDMA (Molly, Ecstasy)

Selected References:

- Bloor M, et al. 2012. Tramadol in pregnancy and lactation. *Int J Obstet Anesth* 21:163-7.
- Bowie AC, et al. 2022. Prescribed opioid analgesics in early pregnancy and the risk of congenital anomalies: a population-based cohort study. *CMAJ*. 194(5):E152-E162.
- Ferrer E, et al. 2025. Tramadol during pregnancy: risk of adverse pregnancy outcome and major congenital anomalies. A comparative study in the EFEMERIS database. *Pharmacoepidemiol Drug Saf*. 34(4):e70143.
- Hartenstein S, et al. 2010. Neonatal abstinence syndrome (NAS) after intrauterine exposure to tramadol. *J Perinat Med* 38: 695-6.
- Ilett KF, et al. 2008. Use of a sparse sampling study design to assess transfer of tramadol and its o-desmethyl metabolite into transitional breast milk. *Br J Clin Pharmacol*. 65:661-6.
- Kallen B & Reis M. 2015. Use of tramadol in early pregnancy and congenital malformation risk. *Reprod Toxicol*. 23;58:246-251.
- Kaur Makkar J, et al. 2015. Comparison of analgesic efficacy of paracetamol and tramadol for pain relief in active labor. *Clin Anesth*. 27(2):159-63.
- Meyer FP, et al. 1997. Tramadol withdrawal in a neonate. *Eur J Clin Pharmacol* 53: 159-60.
- O'Mara K, et al. 2010. Treatment of neonatal withdrawal with clonidine after long-term, high-dose maternal use of tramadol. *Ann Pharmacother* 44: 1342-4.
- Sawaddiruk P. 2011. Tramadol hydrochloride/acetaminophen combination for the relief of acute pain. *Drugs Today (Barc)*. 47(10):763-772.
- Schuckit MA. 2016. Treatment of opioid-use disorders. *N Engl J Med*. 375:357-68
- Sørensen AMS, et al. 2022. Exposure to tramadol during early pregnancy and risk of spontaneous abortion or major congenital malformations. *Obstet Gynecol*. 139(4):545-553.
- Subedi A. et al. 2013. Analgesic effects of intrathecal tramadol in patients undergoing caesarean section: a randomised, double-blind study. *Int J Obstet Anesth*. 22(4):316-21.
- U.S. Food & Drug Administration. Updated 10/2023. FDA drug safety communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against the use in breastfeeding women. Available from URL: <https://www.fda.gov/Drugs/DrugSafety/ucm549679.htm>
- Willaschek C, et al. 2009. Tramadol withdrawal in a neonate after long-term analgesic treatment of the mother.

Eur J Clin Pharmacol 65: 429-30.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, July 1, 2022.

MDMA (Molly, Ecstasy)

Selected References:

- Abdellatif M, et al. 2019. Association between exposure to macrolides and the development of infantile hypertrophic pyloric stenosis: a systematic review and meta-analysis. *Eur J Pediatr* 178(3):301-314.
- Adair CD, Gunter M, Stovall TG et al. 1998. Chlamydia in pregnancy: A randomized trial of azithromycin and erythromycin. *Obstet Gynecol* 91:165-168.
- Andersson NW, Olsen RH, Andersen JT. 2021. Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study. *BMJ*. 372:n107.
- Bahat Dinur A, et al. 2013. Fetal safety of macrolides. *Antimicrob Agents Chemother* 57(7):3307-11.
- Berard A, et al. 2015. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. *Pharmacoepidemiol Drug Saf* 24(12):1241-1248.
- Cohen I, et al. 1990. Improved pregnancy outcome following successful treatment of chlamydial infection. *JAMA* 263:3160-3163.
- Committee on Drugs, American Academy of Pediatrics. 2001. The transfer of drugs and other chemicals into human breast milk. *Pediatrics* 108:776-89.
- Damkier P, et al. 2019. In utero exposure to antibiotics and risk of congenital malformations: A population-based study. *Am J Obstet Gynecol* 221:648.e1-15.
- Fan H, et al. 2020. Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study. *BMJ* 368:m331.
- Flenady V, et al. 2013. Prophylactic antibiotics for inhibiting preterm labour with intact membranes. *Cochrane Database Syst Rev* 5;12:CD000246.
- FitzSimmons J et al. 1990. Chlamydial infections in pregnancy. *J Reprod Med* 31:19-22, 1986.

- Goldstein LH, et al. 2009. The safety of macrolides during lactation. *Breastfed Med* 4:157-200
- Källén B, Danielsson BR, 2014. Fetal safety of erythromycin. An update of Swedish data. *Eur J Clin Pharmacol* 70(3):355-60.
- Lin KJ, et al. 2013. Safety of macrolides during pregnancy. *Am J Obstet Gynecol* 208(3):221.e1-8.
- Lund M, et al. 2014. Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. *BMJ* 11;348:g1908.
- Marlow N, et al. 2017. The ORACLE Children Study: educational outcomes at 11 years of age following antenatal prescription of erythromycin or co-amoxiclav. *Arch Dis Child Fetal Neonatal Ed* 102(2):F131-F135.
- McCormack WM et al. 1987. Effect on birth weight of erythromycin treatment of pregnant women. *Obstet Gynecol* 69:202-207.
- McGregor JA et al. 1986. Adjunctive erythromycin treatment for idiopathic preterm labor: Results of a randomized, double-blind, placebo-controlled trial. *Am J Obstet Gynecol* 154:98-103.
- Romøren M, et al. 2012. Pregnancy outcome after gestational exposure to erythromycin – a population-based register study from Norway. *Br J Clin Pharmacol* 74(6):1053-62.
- Ryan GM Jr, Abdella TN, McNeeley SG, et al. 1990. Chlamydia trachomatis infection in pregnancy and effect of treatment on outcome. *Am J Obstet Gynecol* 162:34-39.
- Sorensen, HT et al. 2003. Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides. *Scand J Infect Dis* 35:104-6
- WHO Working Group, Bennet PN (ed). 1988. *Drugs and Human Lactation*. Elsevier, Amsterdam, New York, Oxford, pp. 253-4.
- Schachter J et al. 1986. Experience with the routine use of erythromycin for chlamydial infections in pregnancy. *N Engl J Med* 314:276-9.

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, July 1, 2022.

MDMA (Molly, Ecstasy)

Selected References:

- Caballero Bermejo A, et al. 2020. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial. *Trials*; 21(1):794. PMID: 32938496 PMCID: PMC7492787 DOI: 10.1186/s13063-020-04633-3
- Khiali S, et al. 2021. A comprehensive review on sarilumab in COVID-19
- Affiliations expand. *Expert Opin Biol Ther*; 21(5):615-626. PMID: 33161757 DOI: 10.1080/14712598.2021.1847269
- Garcia-Vicuña R, et al. 2020. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. *Trials*; 21(1):772. PMID: 32907638 PMCID: PMC7480631 DOI: 10.1186/s13063-020-04588-5
- No authors listed, 2020. Sarilumab. In: *Drugs and Lactation Database (LactMed)* [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. PMID: 29999974 Bookshelf ID: NBK500915. <https://www.ncbi.nlm.nih.gov/books/NBK500915/> Accessed 01/2022.
- Prieto-Peña D, et al. 2021. Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update. *Pol Arch Intern Med*; 131(2):171-181. PMID: 32550671 DOI: 10.20452/pamw.1543

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.mothertobaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, July 1, 2022.